ArticleF&S reports2026
Possible drug reaction with eosinophilia and systemic symptoms after spironolactone therapy for clinical hyperandrogenism: a case report.
Article in F&S reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To present a case of possible drug reaction with eosinophilia and systemic symptoms (DRESS) after spironolactone and to review existing literature on serious cutaneous adverse reactions to spironolactone. Design: Case report and literature review. Subject: A 29-year-old woman with hyperandrogenism who developed a febrile, pruritic, generalized rash 1 week after initiating spironolactone. Exposure: Discontinuation of spironolactone. Main Outcome Measures: Resolution of symptoms, RegiSCAR diagnostic assessment for DRESS. Results: Symptoms resolved after discontinuation and recurred upon two separate rechallenges. Although laboratory and histopathological data were not available to definitively confirm the diagnosis of DRESS, clinical features were suspicious for DRESS on the basis of RegiSCAR criteria. The patient met five diagnostic criteria, which would classify this as a "possible" case. Other reported cutaneous reactions to spironolactone include linear immunoglobulin A bullous dermatosis and erythema multiforme. Conclusion: Clinicians should be aware of the rare but potentially serious risk of DRESS in patients treated with spironolactone. Prompt recognition, drug discontinuation, and supportive management are essential. Diagnostic confirmation with laboratory studies and skin biopsy should be pursued in suspected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.